HRP20050184B1 - Uporaba alkilfosfoholina u kombinaciji s protutumorskim lijekovima - Google Patents

Uporaba alkilfosfoholina u kombinaciji s protutumorskim lijekovima

Info

Publication number
HRP20050184B1
HRP20050184B1 HRP20050184AA HRP20050184A HRP20050184B1 HR P20050184 B1 HRP20050184 B1 HR P20050184B1 HR P20050184A A HRP20050184A A HR P20050184AA HR P20050184 A HRP20050184 A HR P20050184A HR P20050184 B1 HRP20050184 B1 HR P20050184B1
Authority
HR
Croatia
Prior art keywords
combination
alkylphospholine
tumor drugs
alkyl phosphocholines
phosphocholines
Prior art date
Application number
HRP20050184AA
Other languages
English (en)
Croatian (hr)
Inventor
Jürgen Engel
Günther Eckhard
Herbert Sindermann
Original Assignee
Æterna Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Æterna Zentaris Gmbh filed Critical Æterna Zentaris Gmbh
Publication of HRP20050184A2 publication Critical patent/HRP20050184A2/hr
Publication of HRP20050184B1 publication Critical patent/HRP20050184B1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20050184AA 2002-07-30 2003-07-29 Uporaba alkilfosfoholina u kombinaciji s protutumorskim lijekovima HRP20050184B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39961502P 2002-07-30 2002-07-30
PCT/EP2003/008346 WO2004012744A1 (de) 2002-07-30 2003-07-29 Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten

Publications (2)

Publication Number Publication Date
HRP20050184A2 HRP20050184A2 (en) 2005-04-30
HRP20050184B1 true HRP20050184B1 (hr) 2014-04-11

Family

ID=31495746

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20050184AA HRP20050184B1 (hr) 2002-07-30 2003-07-29 Uporaba alkilfosfoholina u kombinaciji s protutumorskim lijekovima

Country Status (26)

Country Link
US (3) US8389497B2 (cg-RX-API-DMAC10.html)
EP (2) EP1545553B1 (cg-RX-API-DMAC10.html)
JP (1) JP2005535688A (cg-RX-API-DMAC10.html)
KR (3) KR101066804B1 (cg-RX-API-DMAC10.html)
CN (1) CN1302780C (cg-RX-API-DMAC10.html)
AR (1) AR040717A1 (cg-RX-API-DMAC10.html)
AT (1) ATE516036T1 (cg-RX-API-DMAC10.html)
AU (2) AU2003253350B2 (cg-RX-API-DMAC10.html)
BR (1) BR0313048A (cg-RX-API-DMAC10.html)
CA (1) CA2493023C (cg-RX-API-DMAC10.html)
CY (1) CY1111902T1 (cg-RX-API-DMAC10.html)
DK (1) DK1545553T3 (cg-RX-API-DMAC10.html)
ES (1) ES2369535T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20050184B1 (cg-RX-API-DMAC10.html)
IL (1) IL166329A (cg-RX-API-DMAC10.html)
MX (1) MXPA05001203A (cg-RX-API-DMAC10.html)
NO (1) NO335196B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ538428A (cg-RX-API-DMAC10.html)
PL (1) PL375493A1 (cg-RX-API-DMAC10.html)
PT (1) PT1545553E (cg-RX-API-DMAC10.html)
RU (1) RU2005105693A (cg-RX-API-DMAC10.html)
SI (1) SI1545553T1 (cg-RX-API-DMAC10.html)
TW (1) TWI332007B (cg-RX-API-DMAC10.html)
UA (1) UA82322C2 (cg-RX-API-DMAC10.html)
WO (1) WO2004012744A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200500453B (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
UA82322C2 (uk) 2002-07-30 2008-04-10 Центаріс Гмбх Застосування алкілфосфохолінів в комбінації з протипухлинними лікарськими засобами
DE10324911B4 (de) 2003-05-30 2005-08-18 Siemens Ag Röntgenvorrichtung mit partiellem digitalem Detektor und Verfahren zum Betrieb einer solchen
WO2006081452A2 (en) * 2005-01-28 2006-08-03 Robert Birch Co-administration of perifosine with chemotherapeutics
EP1962862B1 (en) * 2005-12-19 2013-09-04 Æterna Zentaris GmbH Alkyl phospholipid derivatives with reduced cytotoxicity and uses therof
US20070167408A1 (en) * 2005-12-19 2007-07-19 Zentaris Gmbh Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
EP1800684A1 (en) * 2005-12-20 2007-06-27 Zentaris GmbH Novel alkyl phospholipid derivatives and uses thereof
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
CN103479604B (zh) * 2007-07-30 2016-08-10 阿迪生物科学公司 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法
AU2009324464B2 (en) * 2008-12-11 2016-05-05 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US8383607B2 (en) 2010-03-31 2013-02-26 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033917A1 (de) * 1998-12-04 2000-06-15 Max-Delbrück-Centrum für Molekulare Medizin Mittel zur tumortherapie auf liposomenbasis die tamoxifen enthalten
WO2002066019A2 (en) * 2001-02-19 2002-08-29 Novartis Ag Cancer treatment
WO2003055522A1 (en) * 2002-01-02 2003-07-10 Pharmacia Italia Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors
WO2005000318A2 (en) * 2003-06-23 2005-01-06 Neopharm, Inc. Method of inducing apoptosis and inhibiting cardiolipin synthesis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2086026T3 (es) * 1991-07-04 1996-06-16 Asta Medica Ag Farmaco con efecto antineoplasico que contiene como sustancia activa (2-(n-metil-piperidino)-etil)-fosfato de octadecilo y procedimiento para su preparacion.
US5942639A (en) * 1991-07-04 1999-08-24 Asta Medica Aktiengesellschaft Process for the preparation of alkylphosphocholines and the production thereof in pure form
US6172050B1 (en) * 1992-07-11 2001-01-09 Asta Medica Aktiengesellschaft Phospholipid derivatives
JP3079993B2 (ja) * 1996-03-27 2000-08-21 日本電気株式会社 真空マイクロデバイスおよびその製造方法
DE19650778C2 (de) * 1996-12-06 2001-01-04 Asta Medica Ag Verwendung von Dopaminrezeptor-Antagonisten in der palliativen Tumortherapie
CA2318260C (en) 1998-01-22 2006-11-21 Asta Medica Ag Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
US6583127B1 (en) 1998-12-21 2003-06-24 Inkeysa. Sa Use of etherlysophospholipids as antiinflammatory agents
ATE450265T1 (de) * 2001-03-23 2009-12-15 Shire Canada Inc Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
WO2003005522A1 (es) 2001-07-04 2003-01-16 Acuna Arturo Tapones para sellado de ductos para redes electricas, telefonicas y de fibra optica.
UA82322C2 (uk) 2002-07-30 2008-04-10 Центаріс Гмбх Застосування алкілфосфохолінів в комбінації з протипухлинними лікарськими засобами
WO2006081452A2 (en) 2005-01-28 2006-08-03 Robert Birch Co-administration of perifosine with chemotherapeutics
US20070167408A1 (en) 2005-12-19 2007-07-19 Zentaris Gmbh Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
US8383607B2 (en) 2010-03-31 2013-02-26 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033917A1 (de) * 1998-12-04 2000-06-15 Max-Delbrück-Centrum für Molekulare Medizin Mittel zur tumortherapie auf liposomenbasis die tamoxifen enthalten
WO2002066019A2 (en) * 2001-02-19 2002-08-29 Novartis Ag Cancer treatment
WO2003055522A1 (en) * 2002-01-02 2003-07-10 Pharmacia Italia Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors
WO2005000318A2 (en) * 2003-06-23 2005-01-06 Neopharm, Inc. Method of inducing apoptosis and inhibiting cardiolipin synthesis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BERKOVIC D ET AL: "The influence of 1-beta-D-arabinofuranosylcytosine on the metabolism of phosphatidylcholine in human leukemic HL 60 and Raji cells." LEUKEMIA: OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K. ENGLAND DEC 1997, Bd. 11, Nr. 12, Dezember 1997 (1997-12),2079-2086 str. *
DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; Februar 1991 (1991-02) SHOJI M ET AL: "Effects of hexadecylphosphocholine on protein kinase C and TPA-induced differentiation of HL60 cells." Database accession no. NLM2051897 XP002256716 & LIPIDS. UNITED STATES FEB 1991, Bd. 26, Nr. 2, Februar 1991 (1991-02), 145-149 str. *
GEORGIEVA MILKA C ET AL: "Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells." CANCER LETTERS. IRELAND 28 AUG 2002, Bd. 182, Nr. 2, 28. August 2002 (2002-08-28), 163-174 str. *
HILGARD P ET AL: "Heterocyclic alkylphospholipids with an improved therapeutic range." ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. UNITED STATES 1996, Bd. 416, 1996,157-164 str. *
SPRUSS T ET AL: "ANTITUMOUR ACTIVITY OF MILTEFOSINE ALONE AND AFTER COMBINATION WITHPLATINUM COMPLEXES ON MXT MOUSE MAMMARY CARCINOMA MODELS" JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, Bd. 119, Nr. 3, 1993,142-149 str. *
STEKAR J ET AL: "Opposite effect of miltefosine on the antineoplastic activity and haematological toxicity of cyclophosphamide." EUROPEAN JOURNAL OF CANCER (OXFORD, ENGLAND: 1990) ENGLAND 1995, Bd. 31A, Nr. 3, 1995, 372-374 str. *

Also Published As

Publication number Publication date
ZA200500453B (en) 2005-08-31
CA2493023C (en) 2012-01-31
EP1545553A1 (de) 2005-06-29
SI1545553T1 (sl) 2011-09-30
US20100190738A1 (en) 2010-07-29
NZ538428A (en) 2006-09-29
CY1111902T1 (el) 2015-11-04
RU2005105693A (ru) 2005-07-10
PL375493A1 (en) 2005-11-28
UA82322C2 (uk) 2008-04-10
US8507710B2 (en) 2013-08-13
JP2005535688A (ja) 2005-11-24
AU2008203060B2 (en) 2011-04-21
KR20130016413A (ko) 2013-02-14
AU2003253350B2 (en) 2008-06-26
NO335196B1 (no) 2014-10-20
HK1080751A1 (en) 2006-05-04
DK1545553T3 (da) 2011-09-12
TWI332007B (en) 2010-10-21
AR040717A1 (es) 2005-04-20
EP1545553B1 (de) 2011-07-13
PT1545553E (pt) 2011-09-12
KR101066804B1 (ko) 2011-09-22
US8389497B2 (en) 2013-03-05
BR0313048A (pt) 2005-06-14
NO20051040L (no) 2005-02-25
CN1671397A (zh) 2005-09-21
ATE516036T1 (de) 2011-07-15
HRP20050184A2 (en) 2005-04-30
US20100189784A1 (en) 2010-07-29
IL166329A (en) 2012-08-30
TW200404073A (en) 2004-03-16
US8551977B2 (en) 2013-10-08
AU2008203060A1 (en) 2008-07-31
MXPA05001203A (es) 2005-06-08
KR20050026028A (ko) 2005-03-14
AU2003253350A1 (en) 2004-02-23
WO2004012744A1 (de) 2004-02-12
KR20110102485A (ko) 2011-09-16
CA2493023A1 (en) 2004-02-12
EP2301551A1 (de) 2011-03-30
US20040097470A1 (en) 2004-05-20
IL166329A0 (en) 2006-01-15
CN1302780C (zh) 2007-03-07
ES2369535T3 (es) 2011-12-01

Similar Documents

Publication Publication Date Title
DE60336734D1 (de) Sidasen
MEP36208A (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
YU21401A (sh) Tetrahidropiridoetri
NO20032759D0 (no) 2-fenylbenzimidazoler og imidazo-[4,5]-pyridiner som SDSI/CHK2-inhibitorerog adjuvanter ved kjemoterapi eller strålingsterapi ved behandlingav kreft
EP1819227A4 (en) PHARMACEUTICAL FORMULATIONS OF DECITABIN
MXPA05005107A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
DK1556058T3 (da) Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
DE50310516D1 (de) Fredericamycin-derivate
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
NO20042035L (no) Forbedret anvendelse av antitumorforbindelse i kreftterapi
CY1111902T1 (el) Χρηση ακυλοφωσφοχολινων σε συνδυασμο με αντινεοπλασματικα φαρμακα
EP1881984A4 (en) INHIBITORS OF NUCLEOSIDE PHOSPHOROLE LASES AND NUCLEOSIDASES
WO2003106384A3 (en) Novel boronic chalcone derivatives and uses thereof
SI1546182T1 (sl) Sestavki in postopki za diagnozo in zdravljenje tumorja
DK1558620T3 (da) Rutheniumkomplekser med anticancervirkning
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
ATE431742T1 (de) Modifizierte zytokine für krebs therapie
MXPA05008817A (es) Derivados de esteres lipidos de nucleotidos.
FR2877667B1 (fr) Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
ATE336244T1 (de) Metallorganisches antitumormittel
ATE406375T1 (de) Antitumor wirksame 2-substituierte d-homoestra-1, 3,5(10)-trien-3-yl sulfamate
ATE397003T1 (de) Ruthenium(ii)-komplexe zur behandlung von tumoren
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
HN2002000129A (es) Nuevos heterociclos 3

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: ZENTARIS GMBH, DE

PNAN Change of the applicant name, address/residence

Owner name: ÆTERNA ZENTARIS GMBH, DE

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20160714

Year of fee payment: 14

PBON Lapse due to non-payment of renewal fee

Effective date: 20170729